Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British journal of haematology Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., Kipps, T. J., Burger, J. A., Stevens, D. A., Sharman, J., Ghia, P., Flinn, I. W., Zhou, C., Ninomoto, J., James, D. F., Tam, C. S. 2019
View details for PubMedID 30740654